Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review

Area of Science:

• Pharmacology
• Infectious Diseases
• Cardiology

Background:

• Dalbavancin, a lipoglycopeptide antibiotic, is derived from teicoplanin and is structurally analogous to vancomycin.
• It is primarily indicated for skin and soft tissue infections.
• Its prolonged half-life of approximately 14 days suggests potential for treating infections requiring extended antibiotic therapy, such as infective endocarditis.

Approach:

• This article reviews existing literature on dalbavancin's use in treating Gram-positive infective endocarditis.
• The review focuses on studies where dalbavancin was administered, often as sequential therapy.
• Data on clinical efficacy and tolerability were analyzed.

Key Points:

• Dalbavancin was predominantly used as sequential therapy after standard antibiotic treatments.
• The overall clinical efficacy of dalbavancin in the reviewed cases was approximately 90%.
• Dalbavancin was generally well-tolerated by patients.

Conclusions:

• Dalbavancin demonstrates significant clinical efficacy and good tolerability for treating infective endocarditis caused by Gram-positive organisms.
• Its long half-life makes it a promising option for sequential therapy in prolonged treatment regimens.
• Further research and clinical experience are needed to fully establish dalbavancin's role in managing infective endocarditis.